Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally.
Excellent balance sheet with proven track record.
Share Price & News
How has Virbac's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: V16's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: V16 exceeded the German Pharmaceuticals industry which returned -11.1% over the past year.
Return vs Market: V16 exceeded the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Virbac's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Virbac undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: V16 (€170.2) is trading below our estimate of fair value (€206.02)
Significantly Below Fair Value: V16 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: V16 is poor value based on its PE Ratio (27x) compared to the Pharmaceuticals industry average (20.5x).
PE vs Market: V16 is poor value based on its PE Ratio (27x) compared to the German market (16.6x).
Price to Earnings Growth Ratio
PEG Ratio: V16 is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: V16 is overvalued based on its PB Ratio (2.7x) compared to the DE Pharmaceuticals industry average (1.7x).
How is Virbac forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: V16's forecast earnings growth (18.1% per year) is above the savings rate (-0.4%).
Earnings vs Market: V16's earnings (18.1% per year) are forecast to grow faster than the German market (14.1% per year).
High Growth Earnings: V16's earnings are forecast to grow, but not significantly.
Revenue vs Market: V16's revenue (5% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: V16's revenue (5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: V16's Return on Equity is forecast to be low in 3 years time (12.9%).
How has Virbac performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: V16 has high quality earnings.
Growing Profit Margin: V16's current net profit margins (5.5%) are higher than last year (2.3%).
Past Earnings Growth Analysis
Earnings Trend: V16's earnings have declined by -7.8% per year over the past 5 years.
Accelerating Growth: V16's earnings growth over the past year (156.5%) exceeds its 5-year average (-7.8% per year).
Earnings vs Industry: V16 earnings growth over the past year (156.5%) exceeded the Pharmaceuticals industry 1.9%.
Return on Equity
High ROE: V16's Return on Equity (9.9%) is considered low.
How is Virbac's financial position?
Financial Position Analysis
Short Term Liabilities: V16's short term assets (€450.9M) exceed its short term liabilities (€372.5M).
Long Term Liabilities: V16's short term assets (€450.9M) exceed its long term liabilities (€398.9M).
Debt to Equity History and Analysis
Debt Level: V16's debt to equity ratio (77.3%) is considered high.
Reducing Debt: V16's debt to equity ratio has reduced from 117.7% to 77.3% over the past 5 years.
Debt Coverage: V16's debt is well covered by operating cash flow (30.8%).
Interest Coverage: V16's interest payments on its debt are well covered by EBIT (6.7x coverage).
Inventory Level: V16 has a high level of physical assets or inventory.
Debt Coverage by Assets: V16's debt is covered by short term assets (assets are 1.1x debt).
What is Virbac's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate V16's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate V16's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if V16's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if V16's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: V16 is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of V16's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Éric Marée (66yo)
Mr. Éric Marée serves as the President and Chief Executive Officer at Virbac SA and served as its Chairman of the Executive Board from December 15, 1999 to 2018 and Member of its Executive Board from 1999 ...
CEO Compensation Analysis
Compensation vs Market: Éric's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD1.93M).
Compensation vs Earnings: Éric's compensation has been consistent with company performance over the past year.
|Chairman of the Executive Board||2.33yrs||€718.75k||0.11% €1.5m|
|CFO & Member of Executive Board||3.83yrs||€400.23k||no data|
|Executive VP of Corporate Development||23.33yrs||€603.12k||0.069% €962.3k|
|Member of Executive Board||23.33yrs||€18.84k||0.010% €145.3k|
|CEO & President||no data||€454.66k||no data|
|Head of Corporate Communications||no data||no data||no data|
|Head of Corporate Human Resources||no data||no data||no data|
|Head of Global Industrial Operations & Corporate Quality Assurance||no data||no data||no data|
Experienced Management: V16's management team is seasoned and experienced (13.6 years average tenure).
|Independent Member of the Supervisory Board||9.25yrs||€21.00k||no data|
|Vice Chairman of Supervisory Board||no data||€21.00k||0.0013% €18.2k|
|Chairwoman of Supervisory Board||14yrs||€116.00k||49.84% €693.9m|
|Non-Voting Member of the Supervisory Board||5.83yrs||€21.00k||no data|
|Independent Member of the Supervisory Board||16.25yrs||€24.00k||0.0052% €72.9k|
|Independent Member of Supervisory Board||0.75yr||no data||no data|
|Member of Supervisory Board||2.58yrs||€21.00k||0.00012% €1.7k|
|Employee Representative of Supervisory Board||1.25yrs||no data||no data|
Experienced Board: V16's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Virbac SA's company bio, employee growth, exchange listings and data sources
- Name: Virbac SA
- Ticker: V16
- Exchange: DB
- Founded: 1968
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €1.392b
- Shares outstanding: 8.43m
- Website: https://corporate.virbac.com
Number of Employees
- Virbac SA
- 13e rue LID - BP 27
- Provence-Alpes-Côte d'Azur
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VIRP||ENXTPA (Euronext Paris)||Yes||Share Capital||FR||EUR||Jan 1992|
|0NM7||LSE (London Stock Exchange)||Yes||Share Capital||GB||EUR||Jan 1992|
|VRBC.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Jan 1992|
|V16||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Jan 1992|
|VIRPP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||EUR||Jan 1992|
Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. The company offers Boviseal, a suspension to prevent intramammary infections; Bovigen Scour, a vaccine used to protect calves against viral and bacterial infections; C.E.T. Veggiedent Fr3sh to treat oral and digestive causes of bad breath; Canigen vaccines; Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Effipro bovis to treat tick, flea, and louse infestations; Epiotic, an ear cleanser; and Eradia to treat clostridium infections and giardiasis. It also provides Fosfosal, a trace mineral injectable supplementation; Grofactor, a growth promoter; Inflacalm, a multi-species anti-inflammatory; Iverhart Max Soft Chew, a chewable tablets to prevent heartworm disease; Milpro, an internal parasiticide tablets; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement. In addition, the company offers Suigen PCV2, a vaccine against porcine circovirus; Penclox, an antibiotic lactating intramammary targeting common bacteria causing mastitis; Physiological eye cleanser, an isotonic solution for cleaning the eye and surrounding areas; Porcistart, a feed supplement; Propofol, an anesthetic; Quadrant to treat infections; and Rabigen mono, a rabies vaccine. Further, it provides Rilexine to treat skin and urinary infections; Sentinel Flavor Tabs and Sentinel Spectrum; Shotapen for bacterial infections; Suigen PCV2, a vaccine for porcine circovirus; Suprelorin, a deslorelin-based implant for the induction of temporary infertility; Tribrissen, a parasiticide oral solution; Ultra-corn used to stimulate the immune system; Veterin, an antibiotic; Veterinary HPM, a specialized petfood; Virbagest, an altrenogest-based progestin; Virbagen Omega, a veterinary interferon; Zenifel, a fogger and spray; and Zoletil, a multi-species general anesthetic. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 21:43|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.